Nasal Spray News and Research

RSS

U.S. Department of Health and Human Services responds to loss of Chiron flu vaccine

Clearly, the loss of the Chiron flu vaccine poses a serious challenge to our vaccine supply for the upcoming flu season. Chiron was to produce between 46-48 million doses of influenza vaccine for the United States.

5 Oct 2004

Each year, between 25 million and 50 million Americans will suffer with the flu

Each year, between 25 million and 50 million Americans will suffer with the fever, chills, body aches and upper respiratory problems brought on by viral influenza, better known as the flu.

30 Sep 2004

Patients with asthma have a higher incidence of nasal polyposis, nasal congestion, and olfactory disturbances

Some 37 million Americans suffer from sinusitis; some of those patients are unfortunate enough to also have asthma, an inflammatory disease of the lungs characterized by reversible airway obstruction.

18 Sep 2004

FDA approves revised labeling for anti-inflammatory corticosteroid nasal spray

AstraZeneca has announced that the U.S. Food and Drug Administration has approved revised labeling for its anti-inflammatory corticosteroid nasal spray RHINOCORT AQUA® (budesonide).

26 Aug 2004

Nicotine replacement therapy shown to help teenagers and women

In the first study, researchers at the Stanford University School of Medicine have found that the nicotine patch seems to work as well, at least initially, for teens as it does for adults. In addition, the patch, the top delivery form of NRT (followed by gum, an inhaler and a nasal spray) worked equally well with or without supplementation by an anti-depressant given to the teens.

21 Aug 2004

Smoking may be on the rise again

The statistics are alarming: About one in five high school seniors smoke cigarettes daily. Yet nearly half a million Americans die prematurely from tobacco-related disease and smoking is projected to in some way kill one third of all smokers.

15 Aug 2004

FDA today alerted consumers not to purchase or use a recalled lot of DU brand nasal decongestant spray

FDA today alerted consumers not to purchase or use a recalled lot of DU brand nasal decongestant spray (distributed by Drugs Unlimited, of Puerto Rico) because it may be contaminated with Burkholderia cepacia – a bacterium that could cause serious, potentially life-threatening infections in some patients. Individuals with compromised immune systems, especially those with cystic fibrosis, could be at risk.

17 May 2004

Study shows ZOMIG nasal spray to be an effective treatment for migraine headaches

Results of a new multicenter U.S. study of almost 1,900 patients experiencing more than 3,400 migraine attacks confirm that treatment with ZOMIG(R) (zolmitriptan) Nasal Spray provides a very fast onset of action and long-lasting relief from migraine headache and associated symptoms.

27 Apr 2004

EU gives 32 million Euro for vaccines to stop tuberculosis

The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.

23 Mar 2004

Olopatadine nasal spray shown to minimise hay fever

Alcon announced today results from a Phase III clinical trial demonstrating that olopatadine nasal spray, a nasal formulation of its market leading ophthalmic anti-allergy product, Patanol(R) ophthalmic solution, reduced seasonal allergic rhinitis (SAR) symptoms compared to placebo.

22 Mar 2004